- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02673437
Rivaroxaban ACS Specialist Cohort Event Monitoring Study (ROSE ACS)
An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO®) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Hampshire
-
Southampton, Hampshire, United Kingdom, SO31 1AA
- Drug Safety Research Unit (for data collation and analysis only)
-
Southampton, Hampshire, United Kingdom, SO31 1AA
- Drug Safety Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- Age 18 years or above
- Patients newly prescribed rivaroxaban in any combination with standard oral antiplatelet therapy for the indication of secondary prevention in patients after ACS
- Patients prescribed dual antiplatelet therapy (contextual cohort) for the indication of secondary prevention after ACS
- Patients have provided signed, informed consent
Exclusion criteria:
- Patients prescribed with oral anticoagulants including rivaroxaban within 6 months prior to the index date for any indication
- Patients commenced rivaroxaban between date of market launch (28th October 2014) for the indication of secondary prevention after ACS and study start (18th September 2015)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Rivaroxaban group
Patients who have been prescribed rivaroxaban and antiplatelet therapy for the prevention of atherothrombotic events following ACS.
|
This is a non-interventional study
|
Alternative dual antiplatelet therapy
Patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS
|
This is a non-interventional study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative incident risk of major bleeding, overall and stratified by the following bleeding sites: intracranial, gastrointestinal, urogenital.
Time Frame: During 12 weeks after initiation of treatment with rivaroxaban or alternative anticoagulant therapy
|
Cumulative incident risk of major bleeding according to the Thrombolysis In Myocardial Infarction (TIMI) classification of non-coronary artery bypass grafting (non-CABG) Related Bleeding, occurring in the 12 week observation period, overall and stratified by the following bleeding sites: intracranial, gastrointestinal, urogenital.The cumulative incidence will be calculated according to the formula: Total number of new cases during 12 week observation period x 100 / Population initially at risk If the observed cumulative incidence from this study falls within the range expected as set by the precision limits of cumulative incidence from clinical trial data, then the null hypothesis (of no difference) will not be rejected. |
During 12 weeks after initiation of treatment with rivaroxaban or alternative anticoagulant therapy
|
Rate of major bleeding, overall and stratified by the following bleeding sites: intracranial, gastrointestinal, urogenital.
Time Frame: During 12 weeks after initiation of treatment with rivaroxaban or alternative anticoagulant therapy
|
During 12 weeks after initiation of treatment with rivaroxaban or alternative anticoagulant therapy
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROSE ACS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
Clinical Trials on This is a non-interventional study
-
Sanguine BiosciencesRecruiting
-
Hull University Teaching Hospitals NHS TrustUniversity of YorkRecruiting
-
Amicus TherapeuticsEngage Health Inc.CompletedFabry DiseaseUnited States
-
University Hospital HeidelbergCompletedEmergencies | COVID-19 PandemicGermany
-
University of MalayaMichael J. Fox Foundation for Parkinson's Research; University of Dundee; Nextcea... and other collaboratorsUnknown
-
International Institute of Behavioral MedicinesRecruiting
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
KK Women's and Children's HospitalUniversity of PlymouthActive, not recruitingCritical Illness | Pediatric ALL | Post Intensive Care Unit SyndromeSingapore
-
Notable LabsCompletedLymphoma | Myelodysplastic Syndromes | Multiple Myeloma | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative NeoplasmSpain, United States, Greece
-
Medlior Health Outcomes Research LtdCompletedChronic Kidney Diseases | Type 2 Diabetes